This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Diagnostics Aid Hologic (HOLX) Q2 Sales Amid Coronavirus?
by Zacks Equity Research
Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in second-quarter fiscal 2020 amid the coronavirus-led economic doldrums.
Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $60.89 in the latest trading session, marking a -0.56% move from the prior day.
Exact Sciences Grows on New Deals, Down on Coronavirus Scare
by Zacks Equity Research
Exact Sciences (EXAS) progressing well in terms of the company's three priorities.
Exact Sciences (EXAS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $42.47, marking a +0.14% move from the previous day.
Exact Sciences (EXAS) Down 39.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On
by Sriparna Ghosal
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Bull of the Day: Guardant Health (GH)
by Kevin Cook
Cancer diagnostics provider who delivered 181% revenue growth and 18,500 tests to patients and labs partners with Amgen
Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y
by Zacks Equity Research
Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.
5 Earnings All-Stars with Spectacular Charts
by Tracey Ryniec
These 5 companies have near perfect earnings surprise track records and their charts are a sight to behold.
Should Growth Investors Buy this Cancer Screening Biotech Stock?
by Benjamin Rains
Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $94.56, moving +1.37% from the previous trading session.
Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $87.93, moving -1.83% from the previous trading session.
Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day
What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.
Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?
by Zacks Equity Research
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Bull of the Day: Exact Sciences (EXAS)
by Kevin Cook
Massive growth in Cologuard may be slowing but cancer detection is their game and multiple targets are in sight
Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?
by Zacks Equity Research
Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.
What's in Store for Align Technology's (ALGN) Q4 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in Q4.
Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?
by Zacks Equity Research
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls
by Zacks Equity Research
Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.
Novavax Rises on Fast Track Designation to Influenza Vaccine
by Zacks Equity Research
The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results
by Zacks Equity Research
Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.